Akebia Therapeutics, Inc. (AKBA)

Akebia Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 5, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	409	415	234	106	395	405
Market Cap Growth	2.91%	77.46%	120.08%	-73.16%	-2.30%	-46.16%
Enterprise Value	441	484	301	121	363	241
Last Close Price	1.54	1.90	1.24	0.58	2.26	2.80
Forward PE	78.97	-	-	-	-	-
PS Ratio	1.68	2.59	1.20	0.36	1.87	1.37
PB Ratio	9.82	-8.43	-7.64	20.30	5.34	1.63
P/TBV Ratio	-	-	-	-	-	8.36
P/FCF Ratio	12.70	-	-	-	-	-
P/OCF Ratio	12.61	-	-	-	-	-
EV/Sales Ratio	1.96	3.02	1.55	0.41	1.71	0.82
EV/EBITDA Ratio	13.68	-	-	39.44	-	-
EV/FCF Ratio	13.71	-	-	-	-	-
Debt / Equity Ratio	4.79	-3.84	-4.72	30.07	2.56	0.51
Debt / EBITDA Ratio	5.34	-	-	18.82	-	-
Asset Turnover	0.79	0.69	0.65	0.66	0.36	0.42
Inventory Turnover	1.92	1.64	2.13	0.77	1.67	0.72
Quick Ratio	1.74	1.07	0.82	1.01	0.79	1.59
Current Ratio	1.94	1.41	1.18	1.43	1.04	1.99
Return on Equity (ROE)	-	-	-	-237.83%	-175.37%	-119.82%
Return on Assets (ROA)	4.80%	-12.49%	-9.30%	-4.89%	-24.27%	-15.41%
Return on Capital (ROIC)	9.35%	-22.81%	-20.14%	-10.17%	-44.71%	-24.88%
Return on Capital Employed (ROCE)	9.50%	-33.10%	-31.40%	-15.30%	-84.90%	-38.20%
Earnings Yield	-3.89%	-16.74%	-22.23%	-88.77%	-71.32%	-95.09%
FCF Yield	7.87%	-9.82%	-10.01%	-69.03%	-63.99%	-27.35%
Buyback Yield / Dilution	-20.49%	-12.53%	-2.56%	-10.14%	-19.85%	-16.95%

Updated Nov 10, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q